Fibroblast Growth Factor Receptor Inhibitors [MoA] class drugs

2 results
  • balversa - erdafitinib tablet, film coated

    (Erdafitinib)
    Janssen Products Lp
    BALVERSA treats adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease progressed after at least one prior systemic therapy. Patient selection requires an FDA-approved companion diagnostic. Not recommended for patients eligible for PD-1/PD-L1 inhibitor therapy who have not yet received it.